Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07226934

An AI-Generated, Personalized Question Prompt List Intervention for Patients With Hematologic Cancers

The goal of this study is to evaluate the feasibility and preliminary efficacy of an artificial intelligence (AI)-generated personalized question prompt list (a list of suggested questions to ask during outpatient appointments) for patients with hematologic cancers. The intervention will involve tailoring a standardized prompt to patients' individual characteristics and concerns. This prompt will then be used to ask Washington University's (WashU) HIPAA compliant ChatGPT to generate personalized question lists for outpatient appointments. Analyses will assess the impact of personalized QPLs on patients' question-asking behavior; communicative self-efficacy; and self-reported amount and satisfaction with information obtained about their disease and its treatment. Sub-analyses will explore patterns in questions generated by WashU ChatGPT. Patients will also provide feedback pertaining to the perceived helpfulness and ease-of-use of WashU-ChatGPT-generated question lists, as well as their attitudes and intentions regarding use of AI chatbots and whether they would engage in pre-appointment AI-assisted question brainstorming independently in the future.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–99 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Washington University School of Medicine

St Louis, Missouri, 63110, United States

Location status: Recruiting

Location contact

Brian D Carpenter, Ph.D.

SUB_INVESTIGATOR

Jessica Hahne, MA, MPH

CONTACT

[email protected]

314-935-6173

Jessica Hahne, MA, MPH

PRINCIPAL_INVESTIGATOR

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Eligibility Criteria as determined by Electronic Health Record (EHR) Screening:

  • Documented diagnosis of lymphoma, as defined by ICD-10 codes C81-C88 or multiple myeloma, as defined by ICD codes C90.0-C90.02
  • Has a scheduled follow-up appointment at a participating outpatient oncology clinic within the next month. Participating clinics include:
  • Dr. David Russler-Germain: Outpatient Lymphoma Clinic
  • Dr. Michael Slade: Outpatient Multiple Myeloma Clinic
  • Dr. Dilan Patel: Outpatient Lymphoma Clinic
  • Undergoing infusion or injection-based systemic therapy intended to cure or manage the disease, as opposed to regimens delivered solely for palliative purposes, at a frequency of once every 1-4 weeks.
  • For eligible patients with lymphoma, this includes, but is not limited to, commonly prescribed treatment combinations such as R-CHOP (Rituximab, Cyclophosphamide, Doxorubicin/Hydroxydaunorubicin, Vincristine, and Prednisone) for Non-Hodgkin Lymphoma, or ABVD (Adriamycin/Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine) for Hodgkin Lymphoma-both regimens that are frequently administered every three weeks
  • For patients with multiple myeloma, eligibility will include patients in the "induction" phase of chemotherapy treatment, which frequently requires patients to come in for outpatient appointments once every four weeks as well as patients in a maintenance phase of treatment that otherwise requires them to attend outpatient appointments at a frequency of every one to four weeks
  • Between the ages of 18-99 at enrollment (Patients older than 99 will be excluded so that the study team is able to elicit questions from WashU ChatGPT using a standardized prompt that describes the patient's age only as specifically as a 10-year decade range (i.e., "I am a patient in my 20's, 30's, 40's, etc. Patients who are 18 or 19 years old will be described in the following manner: "I am a young adult patient in my late teens").
  • Able to consent to medical care independently (does not have a legally authorized representative or documented diagnosis of cognitive impairment)

Eligibility Criteria as determined by subsequent recruitment phone call or In-person approach after a clinic appointment:

  • Does not have visual impairments or English literacy limitations that would interfere with ability to engage in an intervention that requires being able to read material on an electronic device and on paper and communicate aloud during appointments with health care providers, based on patient self-report
  • Able to use email (consent form will be distributed electronically through DocuSign and associated emails), based on successful completion of electronic informed consent

Treatment and study plan

GPT-QPL

Other

A research team member will generate a QPL that is personalized to the patient's demographics (from EHR screening and Baseline Demographic Survey) and concerns (from Distress Thermometer Problem Checklist and Interview).

Other names: AI-Generated, Personalized Question Prompt List

Primary outcomes

  1. Changes in communicative self-efficacy

    Time frame: Appointment 1 (pre-intervention) and appointment 2 (post-intervention) (estimated to be 12 weeks)

    • Communicative self-efficacy is measured by Self-efficacy survey .
    • Dependent samples t-tests will be used to assess within-subject changes.
    • The Self-Efficacy survey consists of two scales containing 10 questions each, with answers ranging from 1=not successful to 5=very successful or 1=not confident to 5=very confident. The total score on each scale ranges from 10-50 with a higher score on Scale 1 (the PEPPI-5) representing higher self-efficacy related to communicating with physicians in general and a higher score on Scale 2 (researcher-designed questions based on Social Cognitive Theory) representing higher self-perceived success at communication with the physician during the immediately preceding appointment.

Secondary outcomes

  1. Changes in perceived amount of cancer information received as measured by an abbreviated version the EORTC QLQ - INFO25

    Time frame: Appointment 1 (pre-intervention) and appointment 2 (post-intervention) (estimated to be 12 weeks)

    • Dependent samples t-tests will be used to assess within-subject changes.
    • The abbreviated version of the EORTC QLQ-INFO 25 being used for this outcome consists of three scales containing a total of 13 questions ranging from 1=not at all to 4=very much. Raw scores are converted using linear transformations. The total score range for each scale is 0-100. A higher score on Scale 1 represents a higher perceived degree of information received about cancer diagnosis, a higher score on Scale 2 represents a higher perceived degree of information received about medical tests, and a higher score on Scale 3 represents a higher perceived degree of information received about cancer treatment.
  2. Changes in satisfaction with cancer information received as measured by the EORTC QLQ - INFO25

    Time frame: Appointment 1 (pre-intervention) and appointment 2 (post-intervention) (estimated to be 12 weeks)

    • Dependent samples t-tests will be used to assess within-subject changes.
    • An additional single item scale from the EORTC QLQ - INFO 25 will be used to measure satisfaction with cancer information received. The answer ranges from 1=not at all to 4=very much. The raw score is converted using the same linear transformation as other EORTC QLQ-INFO 25 scales. The total score range is 0-100, and a higher score represents higher satisfaction with cancer information received.
  3. Changes in the number of questions asked during appointments

    Time frame: Appointment 1 (pre-intervention) and appointment 2 (post-intervention) (estimated to be 12 weeks)

    • Number of questions asked is measured by audio recordings of the clinic appointments.
    • Dependent samples t-tests will be used to assess within-subject changes.
  4. Changes in self-reported degree of intention to use AI chatbots for healthcare tasks

    Time frame: Appointment 1 (pre-intervention) and appointment 2 (post-intervention) (estimated to be 12 weeks)

    • Self-reported degree of intention is measured by one-item AI Chatbot Use survey consisting of a 7-point Likert Scale question asking how frequently participants intend to use AI chatbots for healthcare tasks within the next month. The answer ranges from 1=Never to 7=Several times a day. The total score range is 1-7, and a higher score represents more frequent intended use of AI chatbots for healthcare tasks.
    • Dependent samples t-tests will be used to assess within-subject changes.

Study contacts

Contact information is provided by the study sponsor or research team.

Jessica Hahne, MA, MPH

CONTACT

[email protected]

314-935-6173

Sponsors and collaborators

Lead sponsor

Washington University School of Medicine

Other

Registry information

Official study title

Feasibility and Preliminary Efficacy of GPT-QPL: An AI-Generated, Personalized Question Prompt List Intervention for Patients With Hematologic Cancers

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Nov 12, 2025
Registry last updated
Jun 1, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.